Literature DB >> 9701242

Thrombin receptor overexpression in malignant and physiological invasion processes.

S Even-Ram1, B Uziely, P Cohen, S Grisaru-Granovsky, M Maoz, Y Ginzburg, R Reich, I Vlodavsky, R Bar-Shavit.   

Abstract

Although the involvement of soluble and matrix-immobilized proteases in tumor cell invasion and metastasis is well recognized, the role of proteolytically activated cell surface receptors has not been elucidated. We report here that thrombin receptor, a member of the protease-activated receptor family, is preferentially expressed in highly metastatic human breast carcinoma cell lines and breast carcinoma biopsy specimens. Introduction of thrombin receptor antisense cDNA considerably inhibited the invasion of metastatic breast carcinoma cells in culture through a reconstituted basement membrane. During placental implantation of the human embryo, thrombin receptor is transiently expressed in the invading cytotrophoblasts. These results emphasize the involvement of thrombin receptor in cell invasion associated with tumor progression and normal embryonic development.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701242     DOI: 10.1038/nm0898-909

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  128 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

2.  Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1.

Authors:  Prafull S Gandhi; Zhiwei Chen; Enrico Di Cera
Journal:  J Biol Chem       Date:  2010-03-17       Impact factor: 5.157

Review 3.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

Review 4.  Platelets: linking hemostasis and cancer.

Authors:  Shashank Jain; John Harris; Jerry Ware
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

5.  Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.

Authors:  Gabriel J Villares; Maya Zigler; Andrey S Dobroff; Hua Wang; Renduo Song; Vladislava O Melnikova; Li Huang; Russell R Braeuer; Menashe Bar-Eli
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 6.  G protein-coupled receptor sorting to endosomes and lysosomes.

Authors:  Adriano Marchese; May M Paing; Brenda R S Temple; JoAnn Trejo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

7.  ncRuPAR inhibits gastric cancer progression by down-regulating protease-activated receptor-1.

Authors:  Long Liu; Bing Yan; Zhihui Yang; Xiaodong Zhang; Qunhao Gu; Xiaoqiang Yue
Journal:  Tumour Biol       Date:  2014-05-12

8.  Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia.

Authors:  Michal Reichert
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-24

9.  Protease activated receptors in cardiovascular function and disease.

Authors:  Junor A Barnes; Shamjeet Singh; Aldrin V Gomes
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.